Enhanced complement consumption in neuromyelitis optica and Behçet's disease patients

Journal of Neuroimmunology

Volumn 233, Issue 1-2, 2011, Pages 211-215

  Tüzün, Erdem ^a   Kürtüncü, Murat ^b   Türkoǧlu, Recai ^c   Içöz, Sema ^a   Pehlivan, Münevver ^a   Birişik, Ömer ^a   Eraksoy, Mefküre ^a   Akman Demir, Gulsen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Beh et's disease; Complement; Disability; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BEHCET DISEASE; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADOLESCENT; ADULT; BEHCET SYNDROME; COMPLEMENT ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; UP-REGULATION; YOUNG ADULT;

EID: 79953314010     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.11.010     Document Type: Article

References (33)

1. Adinolfi M., Lehner T. C9 and factor B as acute phase proteins and their diagnostic and prognostic value in disease. Exp. Clin. Immunogenet. 1988, 5:123-132.
2. Aggarwal A., Bhardwaj A., Alam S., Misra R. Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:189-192.
3. Akman-Demir G., Serdaroglu P., Tasçi B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999, 122:2171-2182.
4. Bardak Y., Aridoǧan B.C. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul. Immunol. Inflamm. 2004, 12:53-58.
5. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
6. Brück W., Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol. Sci. 2003, 24:S265-S267.
7. de Seze J., Stojkovic T., Ferriby D., Gauvrit J.Y., Montagne C., Mounier-Vehier F., Verier A., Pruvo J.P., Hache J.C., Vermersch P. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J. Neurol. Sci. 2002, 197:57-61.
8. Delasnerie-Laupretre N., Prevot D., Martin-Mondiere C., Eizenbaum J.F., Degos J.D., Sobel A.T. Serum and cerebrospinal fluid C2 in multiple sclerosis. J. Clin. Lab. Immunol. 1981, 6:23-25.
9. Fan R., Tenner A.J. Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation. J. Neuroinflammation 2005, 2:1.
10. Halawa I., Lolli F., Link H. Terminal component of complement C9 in CSF and plasma of patients with MS and aseptic meningitis. Acta Neurol. Scand. 1989, 80:130-135.
11. Hinson S.R., McKeon A., Fryer J.P., Apiwattanakul M., Lennon V.A., Pittock S.J. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 2009, 66:1164-1167.
12. i̇çöz S., Tüzün E., Kürtüncü M., Durmuş H., Mutlu M., Eraksoy M., Akman-Demir G. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int. J. Neurosci. 2010, 120:71-75.
13. Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:1078-1080. International Study Group for Behçet's Disease.
14. Jans H., Heltberg A., Zeeberg I., Kristensen J.H., Fog T., Raun N.E. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol. Scand. 1984, 69:34-38.
15. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., Vincent A., Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 2008, 4:202-214.
16. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., Lang W., Reindl M., Vincent A., Kristoferitsch W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
17. Jongen P.J., Daelmans H.E., Bruneel B., den Hartog M.R. Humoral and cellular immunologic study of cerebrospinal fluid in a patient with Behçet encephalitis. Arch. Neurol. 1992, 49:1075-1078.
18. Lee J.H., Cho S.B., Bang D., Oh S.H., Ahn K.J., Kim J., Park Y.B., Lee S.K., Lee K.H. Human anti-alpha-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders. Clin. Exp. Rheumatol. 2009, 27:S63-S66.
19. Mold C., Tamerius J.D., Phillips G. Complement activation during painful crisis in sickle cell anemia. Clin. Immunol. Immunopathol. 1995, 76:314-320.
20. Mollnes T.E., Vandvik B., Lea T., Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J. Neurol. Sci. 1987, 78:17-28.
21. Morgan B.P., Campbell A.K., Compston D.A. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet 1984, 2:251-254.
22. Padilla-Docal B., Dorta-Contreras A.J., Fundora-Hernández H., Noris-García E., Bu-Coifiu-Fanego R., González-Hernández M., Rodríguez-Rey A. C3c intrathecal synthesis evaluation in patients with multiple sclerosis. Arq. Neuropsiquiatr. 2007, 65:800-802.
23. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
24. Prineas J.W., Kwon E.E., Cho E.S., Sharer L.R., Barnett M.H., Oleszak E.L., Hoffman B., Morgan B.P. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 2001, 50:646-657.
25. Rinder C.S., Rinder H.M., Smith M.J., Tracey J.B., Fitch J., Li L., Rollins S.A., Smith B.R. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J. Thorac. Cardiovasc. Surg. 1999, 118:460-466.
26. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-erebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
27. Sabater L., Giralt A., Boronat A., Hankiewicz K., Blanco Y., Llufriu S., Alberch J., Graus F., Saiz A. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J. Neuroimmunol. 2009, 215:31-35.
28. Schwab C., McGeer P.L. Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis. Exp. Neurol. 2002, 174:81-88.
29. Speth C., Stöckl G., Mohsenipour I., Würzner R., Stoiber H., Lass-Flörl C., Dierich M.P. Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J. Virol. 2001, 75:2604-2615.
30. Taşçi B., Direskeneli H., Serdaroglu P., Akman-Demir G., Eraksoy M., Saruhan-Direskeneli G. Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behçet patients. Clin. Exp. Immunol. 1998, 113:100-104.
31. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., Geraldes R., Vale T., Jacob A., Palace J., Maxwell S., Beeson D., Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 2008, 65:913-919.
32. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
33. Zhang B., Jiang Y., Yang Y., Peng F., Hu X. Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol. Lett. 2008, 29:256-260.